Cell & Gene: The Podcast
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
Episodes
102 episodes
CRI’s Response to NIH Cuts with Alicia Zhou, Ph.D.
In this episode of the Cell & Gene podcast, Host Erin Harris speaks with Alicia Zhou, Ph.D., CEO of the Cancer Research Institute (CRI), about CRI’s mission to advance cancer immunotherapy and the critical role of federal funding, particula...
•
Episode 101
•
38:12
Rethinking CGT Biotech Growth & Investment with Audrey Greenberg
On the 100th episode of Cell & Gene: The Podcast, Host, Erin Harris, sits down with Audrey Greenberg, Founder and CEO of AG Capital Advisors. Audrey is the award-winning executive, board director, and strategic advisor with a proven track r...
•
Episode 100
•
28:15
Advancing Retinal Gene Therapy with Atsena Therapeutics' Dr. Kenji Fujita
In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics. Atsena develops treatments for inherited retinal diseases, inc...
•
Episode 99
•
14:53
Harnessing the Power of Cord Blood Tregs with Cellenkos' Dr. Simrit Parmar
In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies for autoimmune and inflammatory diseases. Dr...
•
Episode 98
•
34:57
CGT Manufacturing: Distributed & Digital with Deloitte Consulting's Omkar Kawalekar, Ph.D.
Omkar Kawalekar, Ph.D., Senior Manager, NextGen Therapies Manufacturing & Supply Chain Lead, Deloitte Consulting joins Host Erin Harris to share his expert take on how distributed manufacturing models address capacity constraints and supply...
•
Episode 97
•
28:42
Inside Gene Therapies for Cardiac Care with Tenaya Therapeutics' Faraz Ali
In this episode, Erin Harris sits down with Faraz Ali, CEO of Tenaya Therapeutics, to explore the cutting-edge world of gene therapies for heart diseases. As Tenaya makes significant strides in developing innovative treatments, Ali shares insig...
•
Episode 96
•
35:38
The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.
Helen Sabzevari, Ph.D., President and CEO of Precigen, joins Host, Erin Harris to discuss how the company utilizes gorilla adenovirus vectors. These vectors offer significant advantages in delivering large genetic payloads, a crucial factor in ...
•
Episode 95
•
26:49
The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan
Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for ...
•
Episode 94
•
24:24
Lessons in Automation with Roswell Park Comprehensive Cancer Center's Christopher Choi, Ph.D.
Cell & Gene: The Podcast Host Erin Harris talks to Christopher Choi, Ph.D., MBA, SVP Industry Partnership, Director of GMP and Cell Manufacturing Facility, and Associate Professor of Oncology at Roswell Park Comprehensive Cancer Center abou...
•
Episode 93
•
14:49
Can Gene Therapy Be the Solution for CHF with AskBio's Dr. Lothar Roessig
Cell & Gene: The Podcast Host Erin Harris talks to Lothar Roessig, M.D., SVP, Integrated Product Team Lead, Congestive Heart Failure at Asklepios BioPharmaceutical, Inc. (AskBio) about the biggest challenges in developing gene therapies for...
•
Episode 92
•
21:08
Inside a Dopamine-Restoring Cell Therapy for PD with BlueRock Therapeutics' Dr. Amit Rahkit
On this episode of Cell & Gene: The Podcast, Host Erin Harris, invites BlueRock Therapeutics' Dr. Amit Rhakit to take a deep dive into therapy options for Parkinson's disease (PD). They discuss how BlueRock's bemdaneprocel's mechanism of ac...
•
Episode 91
•
31:14
Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene
Rita Johnson-Greene, COO at Alliance for Regenerative Medicine (ARM) joined Cell & Gene: The Podcast Host, Erin Harris, on site during 2024 Meeting on the Mesa to record their discussion. Johnson-Greene shared information about the Joint Cl...
•
Episode 90
•
21:39
Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams
On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Dennis Williams, Senior Vice President of Late Stage Development at Adaptimmune. Williams shares valuable insights into the groundbreaking world of TCR T-cell therapies,...
•
Episode 89
•
20:52
Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte
This episode of Cell & Gene: The Podcast was recorded on site during ARM's 2024 Meeting on the Mesa in Phoenix. Tune in to hear Host Erin Harris talk to Miguel Forte, M.D., Ph.D., CEO of Kiji Therapeutics, President of ISCT, and Executive C...
•
Episode 88
•
25:26
Pioneering Next-Gen TCR Therapies in Solid Tumors with Neogene Therapeutics’ Carsten Linnemann, Ph.D.
Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) therapies for solid cancers. They talk t...
•
Episode 87
•
14:18
Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge
Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market developed to restore vision in retinal diseases lik...
•
Episode 86
•
22:00
A New Approach to Genome Engineering with Tessera Therapeutics' Dr. Michael Severino
Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses ...
•
Episode 85
•
28:06
Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts
Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is t...
•
Episode 84
•
25:13
CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D.
Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program fo...
•
Episode 83
•
27:58
Identifying Drug Development Opportunities for DMD with CureDuchenne
Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDu...
•
Episode 82
•
29:55
Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington
Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-...
•
Episode 81
•
21:01
TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.
KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical stud...
•
Episode 80
•
35:30
Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft
Strand Therapeutics' CEO and Co-Founder Jake Becraft joins Erin Harris to discuss genetic regulation and how the company's programmable mRNA constructs combine genes for self-replication derived from RNA viruses with genetically programmed logi...
•
Episode 79
•
27:52
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko
Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of t...
•
Episode 78
•
14:52
The Current State of the Global Regulatory Landscape with ISCT's Dr. Bambi Grilley
Dr. Bambi Grilley is Professor of Pediatrics and the Director of Clinical Research and Early Product Development for the Center of Cell and Gene Therapy (CAGT) at Baylor College of Medicine AND she is Chief Regulatory Officer at ISCT. Dr. Grill...
•
Episode 77
•
25:21